Clinical Trial Update: Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 dose-escalation trial of regorafenib in advanced hepatocellular carcinoma is ongoing but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Stivarga (regorafenib)

Snippet

Sponsor: Instituto do Cancer do Estado de São Paulo | Conditions: Liver Cancer, Hepatocellular Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING